Who
Jason Shand Robins
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Ocular Therapeutix.
In numbers
- Trades disclosed
- 6
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 20 Jan 2026
- Last trade
- 10 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 12 Jun 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —15,441 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,024 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,024 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —15,441 at $0.00 | filing |
| 20 Jan 2026filed 22 Jan 2026 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,000 at $0.00 | filing |
| 20 Jan 2026filed 22 Jan 2026 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.